Review Article

Regulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in Cancer

Zahava Siegfried, 1 Serena Bonomi, 2 Claudia Ghigna, 2 and Rotem Karni 1

1 Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School Ein Kerem, 91120 Jerusalem, Israel
2 Institute of Molecular Genetics, National Research Council (IGM-CNR), Via Abbiategrasso 207, 27100 Pavia, Italy

Correspondence should be addressed to Rotem Karni; rotemka@ekmd.huji.ac.il

Received 20 June 2013; Accepted 26 July 2013

Academic Editor: Claudio Sette

Copyright © 2013 Zahava Siegfried et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alternative splicing is a fundamental step in regulation of gene expression of many tumor suppressors and oncogenes in cancer. Signalling through the Ras-MAPK and PI3K-mTOR pathways is misregulated and hyperactivated in most types of cancer. However, the regulation of the Ras-MAPK and PI3K-mTOR signalling pathways by alternative splicing is less well established. Recent studies have shown the contribution of alternative splicing regulation of these signalling pathways which can lead to cellular transformation, cancer development, and tumor maintenance. This review will discuss findings in the literature which describe new modes of regulation of components of the Ras-MAPK and PI3K-mTOR signalling pathways by alternative splicing. We will also describe the mechanisms by which signals from extracellular stimuli can be communicated to the splicing machinery and to specific RNA-binding proteins that ultimately control exon definition events.

1. Introduction

In the past several decades cancer research has focused on genetic alterations such as mutations, copy number variations, and translocations that are detected in malignant tissues and contribute to the initiation and progression of cancer. In recent years it is becoming clear that epigenetic changes, including transcriptional and posttranscriptional alterations, also play a major role in cancer development and thus should be the direction of future research [1–4]. Mutations and copy number variations in splicing regulators have been identified in several types of cancer, supporting the notion that changes in splicing fidelity contribute to cancer development [5–9].

Alternative splicing plays a major role in cancer development and progression as many tumor suppressors and oncogenes are modulated by alternative splicing [10, 11]. However, the role of alternative splicing regulators in cancer development is mostly unknown, and only recently the first direct evidence for an oncogenic role of a splicing factor has been shown [9, 12–15].

The Ras-MAPK and PI3K-mTOR signalling pathways are deregulated in many cancers by genetic and epigenetic aberrations [16–18]. Several key components in these pathways, such as Ras, B-RAF, C-RAF, MEK1, PI3K, and Akt, are activated by mutations or gene amplifications, while other components that inhibit these pathways, such as PTEN, LKB1, and TSC1/2, are inactivated by genomic deletions and mutations [16–20]. Pharmacological inhibitors of enzymes in these pathways, such as BRAF inhibitors and mTOR inhibitors, are already being used in clinical settings to treat cancer, while others (PI3K and MEK1 inhibitors) are in advanced stages of clinical trials [21–26]. Although the Ras-MAPK and PI3K-mTOR pathways are at the center of intensive research, and many genetic alterations that activate or inactivate these pathways have been discovered, much less is known about the epigenetic and posttranscriptional regulation of these signalling pathways. Recent studies have revealed how these pathways can be regulated by alternative splicing and by splicing regulators and are the focus of this review.

Here, we discuss the intricate relationship between alternative splicing and signalling at different levels: (i) how the
activity of components in the Ras-MAPK signalling pathway is regulated by alternative splicing in cancer cells; (ii) how the activity of components in the PI3K-mTOR pathway is regulated by alternative splicing in cancer cells; (iii) mechanisms by which extracellular stimuli can be communicated to the splicing machinery and to specific RNA-binding proteins that ultimately control exon definition events.

Alternative splicing can affect the activity of signalling effectors contributing to their constitutive (or improper) function. The most well-characterized examples are represented by members of the receptor tyrosine kinase (RTK) family; EGFR, FGFR, INSR, VEGFR, MET, and Ron [2, 19, 27–39]. In addition, recent studies have also focused on members of non-receptor cytosolic protein kinases, such as Src, Ras, and Raf and on non-kinase cytosolic receptors, including androgen and estrogen receptors [20, 40–43] (Table 1).

### 2. Regulation of the Ras-MAPK Pathway by Alternative Splicing

Downstream to RTK activation, the small GTPase Ras is loaded with GTP and activated. Of the three genes encoding Ras proteins (K-Ras, H-Ras, and N-Ras), K-Ras and H-Ras can include or exclude an exon termed IDX and generate

### Table 1: Alternative splicing of Ras-MAPK and PI3K-mTOR signaling components.

| Signalling component | Gene name | Splicing isoform activity | Type of cancer | Reference number |
|----------------------|-----------|---------------------------|----------------|------------------|
| RTK                  | EGFR      | Constitutively active receptor/soluble decoy isoform, enhanced signalling, survival, and tumorigenicity. | Glioblastoma, lung | [28, 47–49, 51, 56–58] |
| RTK                  | RON       | Constitutively active receptor, enhanced signalling, invasion, and motility. | Glioblastoma, colon, breast, and gastric | [34, 35] |
| RTK                  | MET       | Constitutively active receptor/soluble decoy isoform, enhanced/reduced signalling, invasion, and motility. | Ovarian, lung, and HCC | [38, 39] |
| RTK                  | FGFR      | Induction of EMT, invasion, and motility. | Prostate, pancreatic, and breast | [28, 29, 36, 61] |
| RTK                  | INSR      | Differential ligand binding (IGF-II) and oncogenic activity. | HCC, thyroid, and ovarian | [31, 37] |
| RTK                  | VEGFR     | Soluble decoy isoform, enhanced/reduced angiogenesis, and survival. | Lung, breast | [28, 32] |
| Cytosolic kinase     | Fyn       | Enhanced/reduced kinase activity, survival of epithelial cells. | Unknown | [43] |
| Cytosolic kinase     | mTOR      | Constitutively active kinase, oncogenic activity. | HCC | [75] |
| Cytosolic kinase     | S6K1      | Tumor suppressor/oncogenic isoforms, activates/inhibits mTORC1. | Breast, lung | [14, 78] |
| Cytosolic kinase     | A-Raf     | Enhanced/reduced binding to Ras and activation of the MAPK pathway. | HCC, head, and neck | [45, 46] |
| Cytosolic kinase     | B-Raf     | Enhanced/reduced kinase activity, activation of the MAPK pathway, and resistance to BRAF kinase inhibitors. | Colon, melanoma | [20, 21, 40] |
| Cytosolic kinase     | MEK1      | Alternative pathway with a different substrate. | Unknown | [66, 67] |
| Cytosolic kinase     | ERK1      | Alternative pathway with different substrates. | Unknown | [66, 67] |
| Cytosolic kinase     | MKNK2     | Oncogenic isoform that enhances eIF4E phosphorylation and a tumor-suppressive isoform. | Lung, breast, colon, and pancreas | [14, 68] |
| Phospholipid phosphatase | PTEN      | Active/inactive tumor suppressor. | Unknown | [71] |
| Phospholipid kinase  | PI3K      | Constitutively active kinase, enhanced downstream signalling. | Unknown | [69, 70] |
| Small GTPase         | Ras       | Enhanced/reduced binding to Raf and Rin and activation of the MAPK pathway. | Unknown | [32, 44] |
| GTPase activator (GAP) | TSC2      | Inactivation of a tumor suppressor. | Tuberous sclerosis | [72–74] |
Alternative splicing regulation of the Ras-MAPK pathway. Growth factors and cytokines activate receptor tyrosine kinases (RTKs) which in turn lead to activation of Ras. RTKs can be alternatively spliced to generate soluble truncated isoforms of Ras which act in a dominant-negative manner or constitutively active isoforms which are constitutively active regardless of ligand binding. Ras can be alternatively spliced to generate p19-Ras which cannot activate its downstream effector Raf. GTP-bound p21-Ras activates A-, B-, and C-Raf which can be alternatively spliced to generate inactive dominant-negative isoforms containing only the Ras binding domain (RBD) or constitutively active isoforms containing only the kinase domain. Oncogenic splicing factor hnRNP H inhibits the production of dominant-negative A-Raf isoforms. Raf phosphorylates MAPKK (MEK) which in turn phosphorylates MAPK-ERK. MAPKK1 and ERK1 can generate MAPKK1b and ERK1c, respectively, by alternative splicing to generate a parallel signalling pathway. MAPK-ERK can phosphorylate MNK2, which is alternatively spliced and regulated by the oncogenic splicing factor SRSF1. SRSF1 upregulates a prooncogenic Mnk2b isoform and reduces Mnk2a isoform of this kinase. Blue: tumor suppressors, red: oncogenes, and green: parallel pathway.

p19- or p21-Ras, respectively [44]. p19-Ras cannot interact with A-Raf or Rin1, but binds RACK1 and may act in an antagonistic manner to p21-Ras [42]. Alternative splicing of the cytosolic kinase B-Raf, a downstream effector of the small GTPase Ras in the mitogen-activated protein (MAP) kinase pathway, gives rise to several isoforms devoid of the N-terminal autoinhibitory domain [20]. These constitutively active protein isoforms are able to activate the MAP kinase signalling pathway and to induce tumor formation in nude mice [20] (Figure 1, Table 1). Furthermore, alterations in the splicing profile of signalling components can also play a role in the acquisition of drug resistance. As an example, the mutant B-Raf(V600E) allele generates splicing isoforms that lack the Ras-binding domain and are able to dimerize in a Ras-independent manner [21]. Importantly, B-Raf(V600E) splice transcripts have been detected in several melanoma patients with acquired resistance to vemurafenib, an inhibitor of Raf activity used in clinical practice [21]. In addition, two truncated splicing isoforms of the cytosolic kinase A-Raf, another member of the Raf kinase family, negatively regulate A-Raf (Raf1) kinase activity by sequestering the upstream Ras GTPase activator [45, 46] (Figure 1). A-Rafshort, which arises from retention of introns 2 and 4 is a 171-amino acid protein lacking two-thirds of the C-terminal region including the kinase domain [46]. In human head and neck carcinomas c-myc can induce high levels of the splicing regulator hnRNP H, which in turn increases expression of the full-length A-Raf protein, while decreasing the expression of A-Rafshort [46]. Another truncated isoform is DA-Raf1, which contains a premature termination codon, due to intron 6 retention. This isoform comprises of only the N-terminal Ras-binding domain of A-Raf [45]. Its overexpression impairs the tumorogenic potential of mutant K-Ras transformed mouse NIH3T3 fibroblasts in nude mice [45]. Although identified in murine cell lines, it can also affect the activity of human A-Raf. In a similar fashion, B-Raf truncated splicing variants devoid of kinase activity have been recently identified in colorectal cancer cells [40]. These truncated B-Raf splicing variants are generated through several alternative splicing events, such as skipping of exons 14-15 or inclusion of one of the additional exons 15b, 16b, and 16c, resulting in premature stop codons [40].

The Ras/Raf/MAPK cascade can be activated by the extracellular ligand receptor (EGFR/ErbB1), a member of the ErbB receptor tyrosine kinase family, which is frequently mutated and overexpressed in different human cancers, including glioma, non-small-cell lung carcinoma, ovarian carcinoma, and prostate carcinoma [47]. The most studied EGFR variant is the type III epidermal growth factor receptor (EGFRvIII) (also referred to as ΔEGFR or de2-7 EGFR), containing an inframe deletion of exons 2–7 that can be generated either by gene rearrangement or altered pre-mRNA processing [48, 49]. EGFRvIII lacks a portion of the extracellular ligand-binding domain, is constitutively active in a ligand-independent manner, and confers growth advantage to cancer cells [49, 50] (Figure 1). The selective expression of EGFRvIII in several tumors, but not in normal tissues, makes it an extremely attractive target for anticancer therapy [50]. Another splicing isoform of EGFR, called de4 EGFR, is produced by skipping of exon 4. Similar to EGFRvIII, de4 EGFR undergoes ligand-independent activation and self-dimerization and displays transformation capabilities as well as metastasis-promoting potential [51]. Not only is de4 EGFR detectable in several human tumors, including glioma, prostate, and ovarian, but also its expression correlates with the malignant degree of glioblastomas [51].

A fascinating example of the link between alternative splicing and signalling cascades has been recently provided by studying the metabolic effects, increased glucose uptake and lactate production, of EGFR activation in human cancer cells. The ability of EGFR activation to modulate the metabolism of cancer cells requires the expression of the PKM2 splicing isoform of pyruvate kinase M (PKM) [52], the enzyme that catalyzes the final step of glycolysis. There are two variants of PKM which are generated through alternative splicing of two mutually exclusive exons: exon 9 included in PKM1 transcripts and exon 10 in PKM2. The choice between exon 9 and 10 is controlled by polyadenylation tract binding protein (PTB, also known as PTBP1 or hnRNP I) and hnRNP A1/A2 that bind to sequences flanking exon 9, thus inhibiting the selection of exon 9 and promoting exon 10 inclusion [53, 54].
EGFR activation acts at different levels in the expression of PKM2 by increasing transcription of both PTB and PKM genes. Yang and collaborators have recently reported that EGFR upregulation of PKM2, but not PKM1, requires NF-κB activation, which is mediated by PLCγ1 and PKCe monoubiquitylation-dependent IKKbeta activation [52, 55]. Moreover, RNAi-mediated knock-down experiments indicate that PTB mediates the effect of EGFR on splicing of the PKM gene but not on transcription. Thus, a coordinated transcription-splicing program controlled by EGFR activation is responsible for the expression of the PKM2 isoform and for the distinctive metabolic features of cancer cells.

Another interesting example of regulation of the Ras-MAPK pathway by alternative splicing is the observation made by Cartegni’s group that intronic polyadenylation, concomitantly (and in competition) with pre-mRNA splicing, can generate truncated soluble receptor tyrosine kinases (RTKs). These isoforms lack the anchoring transmembrane domain and the intracellular kinase domain and can act as dominant-negative regulators [28] (Figure 1). These secreted decoy receptors can shut down the relevant tumorigenic signalling pathways by titrating out the ligand or by trapping the wild-type receptors in nonfunctional heterodimers [28]. In particular, for the vascular endothelial growth factor receptor 2 (VEGFR2/KDR), the pivotal molecule in controlling VEGF-dependent functions, the expression of the dominant-negative sKDR strongly inhibited the angiogenesis process in both primary HUVEC endothelial cells and in the same cells exposed to conditioned media and simultaneously treated with VEGF-A. Thus, artificially increasing production of these truncated soluble receptors could be a valid approach to interfere with angiogenic paracrine and autocrine loops.

Soluble isoforms produced by alternative splicing and containing only the extracellular domain of the protein have also been detected for the EGFR/ErbB1 tyrosine kinase receptor [47, 56]. These truncated soluble EGFR variants have been detected in several cancer types, and their levels, circulating as well as in tumor tissues, have been used as prognostic and predictive markers for ovarian, cervical, lung, and breast cancers [57–59]. Alternative splicing of other tyrosine kinase receptors such as the insulin, IGF-1, FGF, ERBB2, and ERBB4 receptors can also modulate the activation of their downstream signalling pathways [2, 19, 29, 36, 60–65]. An additional example of alternative splicing in the Ras-MAPK pathway is the splicing of MEK1b and ERK1c. MEK1 (MAPKK1) phosphorlates and activates ERK1/ERK2 [66, 67]. MEK1b is a unique splicing isoform of MEK1 which specifically phosphorylates ERK1c, an isoform of ERK1 [66, 67]. Thus, by alternative splicing a parallel pathway is generated, and this confers higher substrate specificity to this branch of the pathway [66, 67] (Figure 1). Another component in the MAPK pathway which is regulated by alternative splicing is the kinase MNK2, which is regulated by the oncogenic splicing factor SRSF1. Upregulation of SRSF1 downregulates the expression of the Mnk2a isoform and induces the expression of the Mnk2b isoform [14] (Figure 1). Mnk2b is a prooncogenic isoform that activates elf4E independently of MAPK activation [14]. Recently, this splicing switch was shown to regulate the resistance of prostate cancer cells to chemotherapy [68]. Altogether, these examples of components of the Ras-MAPK pathway which are regulated by alternative splicing open up the exciting possibility of exploiting dominant-negative splicing isoforms for therapeutic purposes, as antioncogenic agents.

3. Regulation of the PI3K-mTOR Pathway by Alternative Splicing

Upon RTK activation, both the Ras-MAPK and the PI3K-mTOR pathways are activated [16, 17] (Figure 2). Kinase PI3K, which phosphorylates 3,5, phosphoinositides, consists of a regulatory subunit, p85, and a catalytic subunit, p110. Both p85 and p110 undergo alternative splicing which can modulate the activity of PI3K [69, 70] (Figure 2). The tumor suppressor phosphatase PTEN, which counteracts PI3K activity, is also regulated by alternative splicing, and splicing isoforms of PTEN that are inactive and act in a dominant-negative fashion have been detected in Cowden syndrome and in breast cancer [71]. Upon production of phosphoinoside by PI3K, the kinase Akt is recruited to the plasma membrane and is activated by PDK1 [17]. Active Akt phosphorylates and inactivates the tumor suppressor TSC2, which inhibits the small GTPase Rheb. GTP-bound Rheb can activate mTOR. mTOR is an active isoform of mTOR, mTOR phosphorlates S6K1 and 4E-BPI. 4E-BPI phosphorylation induces its release from elf4E, enhancing cap-dependent translation and malignant transformation. Oncogenic splicing factor SRSF1 can affect the alternative splicing of S6K1 inducing oncogenic short isoforms of this kinase (h6A, h6C) which bind mTOR and enhance 4E-BPI phosphorylation and cap-dependent translation. Blue: tumor suppressors, red: oncogenes.
TSC1/TSC2. Both TSC1 and TSC2 tumor suppressors are alternatively spliced although inactivation by alternative splicing has not been demonstrated [72–74]. TSC1/2 inactivates the GTPase Rheb, a small GTPase from the Ras protein family which binds and activates mTOR [18]. Alternative splicing of Rheb is not known. mTOR can undergo alternative splicing to generate an activated form called mTORbeta which is oncogenic, although its regulation and role in human cancer have yet to be demonstrated [75]. Recently it was shown that the splicing factor Sam68 controls alternative splicing of mTOR, reducing the retention of intron 5. Cells from Sam68 knockout mice display reduced levels of mTOR mRNA due to nonsense-mediated decay degradation of the intron-retained transcript and reduced activity of the mTOR pathway [76]. mTOR phosphorylates and activates several substrates. Among the best-characterized mTOR substrates are S6K1, which phosphorylates the ribosomal protein S6 and regulates the translation process [18], and eIF4E-BP1, which is involved in the formation of an active translation initiation complex [14, 18, 77]. Alternative splicing of S6K1 transcripts is controlled by the oncogenic splicing factor SRSF1 [14]. Specifically, SRSF1 promotes the production of short S6K1 isoforms, frequently upregulated in breast cancer cell lines and tumors [14, 78]. These variants display oncogenic properties as they are able to enhance cell transformation, motility, and anchorage-independent growth of breast epithelial cells [78]. The short splicing variants of S6K1 are not substrates of the signalling cascade (Akt/mTOR) but generate a signal loop to activate the mTOR pathway in the absence of external stimuli. Indeed, S6K1 short isoforms are able to bind and increase mTORCI activity, leading to 4E-BP1 inactivation and enhancing translation of several oncoproteins and antiapoptotic genes [78] (Figure 2).

4. Extracellular Stimuli Targeting Components of the Splicing Machinery

Although for a long time transcription factors have been considered the ultimate effectors of the signalling cascade pathways, in the last few years splicing machinery components and alternative splicing regulatory proteins have also been recognized as important targets [79]. The activity of splicing factors is normally regulated through posttranscriptional modifications, mainly phosphorylation [80], and therefore it is not surprising that signalling cascades are involved in misregulation of splicing factors. The PI3K/Akt/mTOR signalling cascade, frequently altered in malignancies [81], has been found to affect the alternative splicing profile of cancer-relevant genes via Akt-dependent phosphorylation of several SR proteins, such as SRSF1 and SRSF5 [82–84]. Alternative splicing factor 45 (SPF45) has also been identified as a target of multiple MAP kinases, such as ERKs (extracellular signal-regulated kinases), JNKs (Jun N-terminal kinases), and p38 MAPK [85]. Interestingly, phosphorylation of SPF45 impacts cell proliferation and cell adhesion programs, through downregulation of the human epidermal growth factor receptor (ErbB2) and regulation of the alternative splicing of the fibronectin 1 gene (FNI), respectively [85].

Signals from the EGF receptor, which activate the PI3K-Akt pathway, induce phosphorylation of the SR protein kinase SRPK1 which in turn phosphorylates SR proteins, such as SRSF1. Phosphorylation of SRSF1 leads to its activation and modulation of the cell's alternative splicing program [86]. The complete landscape of alternative splicing changes by such signals has yet to be elucidated.

Stress signals emanating from osmotic shock and other modes of stress which activate the MEK4-/MEK7-p38-MAPK pathway control cell localization of the splicing factor hnRNP A1 [87–89]. Activation of the p38-MAPK pathway induces hnRNP A1 phosphorylation and export from the nucleus into the cytoplasm [87, 89]. Reducing nuclear hnRNP A1 levels in response to stress is expected to affect many alternative splicing events which have yet to be determined. A very complex and intriguing story has emerged from the study of the multiple functions of SRSF1. SRSF1 is a splicing factor with an oncogenic activity that derives from the activation of the PI3K-Akt pathway, induce phosphorylation of the SR protein kinase SRPK1 which in turn phosphorylates SR proteins, such as SRSF1. Phosphorylation of SRSF1 leads to its activation and modulation of the cell's alternative splicing program [86]. The complete landscape of alternative splicing changes by such signals has yet to be elucidated.

A very complex and intriguing story has emerged from the study of the multiple functions of SRSF1. SRSF1 is a splicing factor with an oncogenic activity that derives from its involvement in the Akt-mTOR pathway [14, 90] (Figure 3). The Akt-dependent phosphorylation of SRSF1 affects its function in splicing regulation and translation. Thus, for instance, upon phosphorylation by Akt, SRSF1 enhances the production of EDA-FN, a splicing isoform of fibronectin 1 (FNI) expressed in various malignancies but undetectable in normal tissues [82, 91]. SRSF1 phosphorylation by Clk (CLK1-4) or SRPK kinases (SRPK1-2) has the opposite effect on EDA-FN splicing, pointing to SRSF1 as a sort of integrator component that can switch between splicing decisions in response to various external cues [91]. This view is further supported by the observation that the effect of SRSF1 on EDA-FN splicing is abrogated by rapamycin, an inhibitor of mTORCI (mTOR complex-1) [82]. SRSF1 is not only a target but also an effector of signalling cascades. Indeed, it is able to activate mTORCI leading to downstream phosphorylation of two
of its substrates; S6K1 kinase and 4E-BP1 [77, 78, 90]. The mechanism by which SRSF1 activates mTORC1 still needs to be clarified. However, mTORC1 activation by SRSF1 bypasses upstream PI3K/Akt signalling and is essential for SRSF1-mediated transformation in nude mice, suggesting that mTOR inhibitors may be useful for treatment of tumors with SRSF1 upregulation [78, 90].

5. Conclusions

Our current knowledge is only the tip of the iceberg in terms of the many mechanisms by which alternative splicing regulates the Ras-MAPK and the PI3K-mTOR signalling pathways. This is also true for the mechanisms by which these signalling cascades regulate the activity of splicing regulators such as SR and hnRNP proteins leading to modulation of the cell’s splicing landscape. The diagnostic and therapeutic potential of manipulating the Ras-MAPK and the PI3K-mTOR pathways, by modulating alternative splicing of components of these pathways, is immense. Detection of alternatively spliced isoforms of key substrates, such as S6K1, might be used to predict the sensitivity of tumors to mTOR inhibitors, enabling better choices of drug treatment in the clinic [78]. Another clinical application concerns resistance of tumors to drugs which, as in the case of B-Raf splicing, can arise by alterations in alternative splicing. Elimination of a drug-binding domain, for example, does not require a genomic change but rather can occur by skipping of the relevant exon, resulting in a new splicing isoform which is drug resistant. Even with all these new findings there still remains a lot to be learned about how alternative splicing regulates signalling and how signalling regulates splicing. This field holds great promise for advancing our understanding of the cancer process and for use in the clinic.

References

[1] S. Bonnal, L. Vigevani, and J. Valcarcel, “The spliceosome as a target of novel antitumour drugs,” Nature Reviews Drug Discovery, vol. 11, no. 11, pp. 847–859, 2012.

[2] C. C. Warzecha and R. P. Carstens, “Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT),” Seminars in Cancer Biology, vol. 22, no. 5–6, pp. 417–427, 2012.

[3] E. Kim, A. Goren, and G. Ast, “Insights into the connection between cancer and alternative splicing,” Trends in Genetics, vol. 24, no. 1, pp. 7–10, 2008.

[4] R. K. Singh and T. A. Cooper, “Pre-mRNA splicing in disease and therapeutics,” Trends in Molecular Medicine, vol. 18, no. 8, pp. 472–482, 2012.

[5] E. Papamannou, M. Cazzola, J. Boulwood et al., “Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts,” New England Journal of Medicine, vol. 365, no. 15, pp. 1384–1395, 2011.

[6] J. W. Harbour, E. D. O. Roberson, H. Anburnathan, M. D. Onken, L. A. Worley, and A. M. Bowcock, “Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma,” Nature Genetics, vol. 45, no. 2, pp. 133–135, 2013.

[7] V. Quesada, A. J. Ramsay, and C. Lopez-Otin, “Chronic lymphocytic leukemia with SF3B1 mutation,” New England Journal of Medicine, vol. 366, no. 26, p. 2530, 2012.

[8] V. Quesada, L. Conde, N. Villamor et al., “Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia,” Nature Genetics, vol. 44, no. 1, pp. 47–52, 2012.

[9] M. Cohen-Eliav, R. Golan-Gerstl, Z. Siegfried et al., “The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers,” The Journal of Pathology, vol. 229, no. 4, pp. 630–639, 2013.

[10] J. P. Venables, “Unbalanced alternative splicing and its significance in cancer,” BioEssays, vol. 28, no. 4, pp. 378–386, 2006.

[11] J. P. Venables, R. Klimck, C. Koh et al., “Cancer-associated regulation of alternative splicing,” Nature Structural & Molecular Biology, vol. 16, no. 6, pp. 670–676, 2009.

[12] R. Jia, C. Li, J. P. McCoy, C.-X. Deng, and Z.-M. Zheng, “SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance,” International Journal of Biological Sciences, vol. 6, no. 7, pp. 806–826, 2010.

[13] C. V. Lefave, M. Squatrito, S. Vorlova et al., “Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas,” EMBO Journal, vol. 30, no. 19, pp. 4084–4097, 2011.

[14] R. Karni, E. De Stanchina, S. W. Lowe, R. Sinha, D. Mu, and A. R. Krainer, “The gene encoding the splicing factor SF2/ASF is a proto-oncogene,” Nature Structural and Molecular Biology, vol. 14, no. 3, pp. 185–193, 2007.

[15] R. Golan-Gerstl, M. Cohen, A. Shilo et al., “Splicing factor hnRNPH regulates tumour suppressor gene splicing and is an oncogenic driver in glioblastoma,” Cancer Research, vol. 71, no. 13, pp. 4464–4472, 2011.

[16] T. L. Yuan and L. C. Cantley, “PI3K pathway alterations in cancer: variations on a theme,” Oncogene, vol. 27, no. 41, pp. 5497–5510, 2008.

[17] R. J. Shaw and L. C. Cantley, “PI3K pathway alterations in cancer,” Nature, vol. 441, pp. 7092, pp. 424–430, 2006.

[18] M. Laplanche and D. M. Sabatini, “mTOR signaling in growth control and disease,” Cell, vol. 149, no. 2, pp. 274–293, 2012.

[19] S. Drullinger, C. Dorad, and A. Eychene, “Alternative splicing in oncogenic kinases: from physiological functions to cancer,” Journal of Nucleic Acids, vol. 2012, Article ID 639062, 14 pages, 2012.

[20] E. Y. Baitei, M. Zou, F. Al-Mohanna et al., “Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma,” Journal of Pathology, vol. 217, no. 5, pp. 707–715, 2009.

[21] P. I. Poulikakos, Y. Persaud, M. Janakiraman et al., “RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E),” Nature, vol. 480, pp. 7377, pp. 387–390, 2011.

[22] Y. Heakal, M. Kester, and S. Savage, “Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma,” Annals of Pharmacotherapy, vol. 45, no. 11, pp. 1399–1405, 2011.

[23] C. M. Barnett, “Everolimus: targeted therapy on the horizon for the treatment of breast cancer,” Pharmacotherapy, vol. 32, no. 4, pp. 383–396, 2012.

[24] K. B. Kim, R. Kefford, A. C. Pavlick et al., “Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor,” Journal of Clinical Oncology, vol. 31, no. 4, pp. 482–489, 2013.
[25] K. T. Flaherty, J. R. Infante, A. Daud et al., “Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations,” *New England Journal of Medicine*, vol. 367, no. 18, pp. 1694–1703, 2012.

[26] S. P. Patel, A. J. Lazar, N. E. Papadopoulos et al., “Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma,” *Cancer*, vol. 119, no. 4, pp. 799–805, 2013.

[27] M. W. Pedersen, V. Tkach, N. Pedersen, V. Berezin, and H. S. Poulsen, “Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility,” *International Journal of Cancer*, vol. 108, no. 5, pp. 643–653, 2004.

[28] S. Vorlová, G. Rocco, C. V. LeFave et al., “Induction of antago-nistic soluble decoy receptor tyrosine kinases by intronic polyA activation,” *Molecular Cell*, vol. 43, no. 6, pp. 927–939, 2011.

[29] C. C. Warzecha, T. K. Sato, B. Nabet, J. B. Hogenesch, and R. P. Carstens, “ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing,” *Molecular Cell*, vol. 33, no. 5, pp. 591–601, 2009.

[30] T. H. Ho, R. S. Savkur, M. G. Poulos, M. A. Mancini, M. S. Swanson, and T. A. Cooper, “Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splic-ing in myotonic dystrophy,” *Journal of Cell Science*, vol. 118, no. 13, pp. 2923–2933, 2005.

[31] R. S. Savkur, A. V. Philips, and T. A. Cooper, “Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy,” *Nature Genetics*, vol. 29, no. 1, pp. 40–47, 2001.

[32] B. Mezquita, J. Mezquita, M. Pau, and C. Mezquita, “A novel intracellular isoform of VEGF-R1 activates Src and promotes cell invasion in MDA-MB-231 breast cancer cells,” *Journal of Cellular Biochemistry*, vol. 110, no. 3, pp. 732–742, 2010.

[33] C. P. Thomas, N. S. Raikwar, E. A. Kelley, and K. Z. Liu, “Alternate processing of Flt1 transcripts is directed by conserved cis-elements within an intronic region of FLT1 that reciprocally regulates splicing and polyadenylation,” *Nucleic Acids Research*, vol. 38, no. 15, Article ID gko198, pp. 5130–5140, 2010.

[34] C. Ghigna, M. De Toledo, S. Bonomi et al., “Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives,” *RNA Biology*, vol. 7, no. 4, pp. 495–503, 2010.

[35] C. Ghigna, S. Giordano, H. Shen et al., “Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene,” *Molecular Cell*, vol. 20, no. 6, pp. 881–890, 2005.

[36] P. Zhang, J. S. Grendorfer, J. Jiao, S. C. Kelpke, and J. A. Thompson, “Alternatively spliced FGFR-1 isoforms differentially modulate endothelial cell activation of c-YES,” *Archives of Biochemistry and Biophysics*, vol. 450, no. 1, pp. 50–62, 2006.

[37] H. Chettouh, L. Fartoux, L. Aoudjehane et al., “Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors,” *Cancer Research*, vol. 73, no. 13, pp. 3974–3986, 2013.

[38] J.-H. Lee, F. G. Chong, C. L. Chong, D. K. Myung, and G. F. V. Wouda, “An alternatively spliced form of Met receptor is tumorigenic,” *Experimental and Molecular Medicine*, vol. 38, no. 5, pp. 565–573, 2006.

[39] Z. Tiran, A. Oren, C. Hermesh et al., “A novel recombinant soluble splice variant of met is a potent antagonist of the hepatocyte growth factor/scatter factor-met pathway,” *Clinical Cancer Research*, vol. 14, no. 14, pp. 4612–4621, 2008.

[40] B. Hirschi and F. T. Kolls, “Alternative splicing of BRAF transcripts and characterization of C-terminally truncated B-Raf isoforms in colorectal cancer,” *International Journal of Cancer*, vol. 133, no. 3, pp. 590–596, 2013.

[41] X. Yang, Z. Guo, F. Sun et al., “Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells,” *Journal of Biological Chemistry*, vol. 286, no. 41, pp. 36152–36160, 2011.

[42] M. Camats, M. Kokolo, K. J. Heesom, M. Ladomery, and M. Bach-Elias, “P19 H-ras induces G1/S phase delay maintaining cells in a reversible quiescence state,” *PLoS ONE*, vol. 4, no. 12, Article ID e8513, 2009.

[43] C. Brignatzen, M. P. Paronetto, S. Opi et al., “Alternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn,” *Molecular and Cellular Biology*, vol. 29, no. 24, pp. 6438–6448, 2009.

[44] S. Guil, N. De La Iglesia, J. Fernández-Larrea et al., “Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras family protein that trafficks to cytoplasm and nucleus,” *Cancer Research*, vol. 63, no. 17, pp. 5178–5187, 2003.

[45] T. Yokoyama, K. Takano, A. Yoshida et al., “DA-Raf1, a com-petent intrinsic dominant-negative antagonist of the Ras-ERK pathway, is required for myogenic differen-tiation,” *Journal of Cell Biology*, vol. 177, no. 5, pp. 781–793, 2007.

[46] J. Rauch, K. Moran-Jones, V. Albrecht et al., “c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway,” *Cancer Research*, vol. 71, no. 13, pp. 4664–4674, 2011.

[47] E. K. Rowinsky, “The erbB family: targets for therapeutic develop-ment against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors,” *Annual Review of Medicine*, vol. 55, pp. 433–457, 2004.

[48] N. Sugawa, A. J. Ekstrand, C. D. James, and V. P. Collins, “Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 87, no. 21, pp. 8602–8606, 1990.

[49] R. Nishikawa, X.-D. Ji, R. C. Harmon et al., “A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 16, pp. 7727–7731, 1994.

[50] U. H. Weidle, D. Maisel, S. Klostermann, E. H. Weiss, and M. Schmitt, “Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer,” *Cancer Genomics and Proteomics*, vol. 8, no. 5, pp. 211–226, 2011.

[51] H. Wang, M. Zhou, B. Shi et al., “Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity,” *Neoplasia*, vol. 13, no. 5, pp. 461–471, 2011.

[52] W. Yang, Y. Xia, Y. Cao et al., “EGFR-induced and PKC epsilon mono-ubiquitylation-dependent NF-kappaB activation upregu-lates PKM2 expression and promotes tumorigenesis,” *Molecular Cell*, vol. 48, no. 5, pp. 771–784, 2012.

[53] C. V. Clower, D. Chatterjee, Z. Wang, L. C. Cantley, M. G. V. Heidena, and A. R. Krainer, “The alternative splicing repressors hsnRNPs AI/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 5, pp. 1894–1899, 2010.

[54] C. J. David, M. Chen, M. Assanah, P. Canoll, and J. L. Manley, “HnRNP proteins controlled by c-Myc deregulate pyruvate
kinase mRNA splicing in cancer," *Nature*, vol. 463, no. 7279, pp. 364–368, 2010.

[55] W. Yang, Y. Zheng, Y. Xia et al., “ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect,” *Nature Cell Biology*, vol. 14, no. 12, pp. 1295–1304, 2012.

[56] J. L. Reiter, D. W. Threadgill, G. D. Eley et al., “Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms,” *Genomics*, vol. 71, no. 1, pp. 1–20, 2001.

[57] A. T. Baron, J. A. Wilken, D. E. Haggstrom, S. T. Goodrich, and N. J. Maihle, “Clinical implementation of soluble EGFR (sEGFR) as a therapeutic serum biomarker of breast, lung and ovarian cancer,” *iDrugs*, vol. 12, no. 5, pp. 302–308, 2009.

[58] S. Maramotti, M. Paci, F. Micciché et al., “Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood,” *Lung Cancer*, vol. 76, no. 3, pp. 332–338, 2012.

[59] C. Halle, M. Lando, D. H. Svendsrud et al., “Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer,” *Clinical Cancer Research*, vol. 17, no. 16, pp. 5501–5512, 2011.

[60] A. Philippou, A. Armakolas, and M. Koutsilieris, “Evidence for the possible biological significance of the igf-1 gene alternative splicing in prostate cancer,” *Frontiers in Endocrinology*, vol. 4, article 31, 2013.

[61] G. Chen, J. Wang, Z. Liu, and M. Kornmann, “Exon III splicing of fibroblast growth factor receptor 1 is modulated by growth factors and cyclin D1,” *Pancreas*, vol. 37, no. 2, pp. 159–164, 2008.

[62] G. Condorelli, R. Bueno, and R. J. Smith, “Two alternatively spliced forms of the human insulin-like growth factor I receptor have distinct biological activities and internalization kinetics,” *Journal of Biological Chemistry*, vol. 269, no. 11, pp. 8510–8516, 1994.

[63] C. Marchini, F. Gabrielli, M. Iezzi et al., “The human splice variant δ16HER2 induces rapid tumor onset in a reporter transgenic mouse,” *PloS ONE*, vol. 6, no. 4, Article ID e18727, 2011.

[64] V. Veikkolainen, K. Varapanta, K. Halkilahti, K. Iljin, M. Sundvall, and K. Elenius, “Function of ERBB4 is determined by alternative splicing,” *Cell Cycle*, vol. 10, no. 16, pp. 2647–2657, 2011.

[65] M. Sundvall, V. Veikkolainen, K. Kurppa et al., “Cell death or survival promoted by alternative isoforms of ErbB4,” *Molecular Biology of the Cell*, vol. 21, no. 23, pp. 4275–4286, 2010.

[66] D. M. Abersold, Y. D. Shaul, Y. Yung et al., “Extracellular Signal-Regulated Kinase 1c (ERK1c), a novel 42-kilodalton ERK, demonstrates unique modes of regulation, localization, and function,” *Molecular and Cellular Biology*, vol. 24, no. 22, pp. 10000–10015, 2004.

[67] Y. D. Shaul, G. Gibor, A. Plotnikov, and R. Seger, “Specific phosphorylation and activation of ERK1c by MEK1b: a unique route in the ERK cascade,” *Genes and Development*, vol. 23, no. 15, pp. 1779–1790, 2009.

[68] L. Adesso, S. Calabretta, F. Barbagallo et al., “Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway,” *Oncogene*, vol. 32, no. 23, pp. 2848–2857, 2013.

[69] S. Fransson, A. Uv, H. Eriksson et al., “p37delta is a new isoform of PI3K p110delta that increases cell proliferation and is overexpressed in tumors,” *Oncogene*, vol. 31, no. 27, pp. 3277–3286, 2012.

[70] E. Lefai, M. Roques, N. Vega, M. Laville, and H. Vidal, “Expression of the splice variants of the p85α regulatory subunit of phosphoinositide 3-kinase in muscle and adipose tissue of healthy subjects and type 2 diabetic patients,” *Biochemical Journal*, vol. 360, no. 1, pp. 117–125, 2001.

[71] S. Agrawal and C. Eng, “Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer,” *Human Molecular Genetics*, vol. 15, no. 5, pp. 777–787, 2006.

[72] M. Hoogeveen-Westerveld, R. Ekong, S. Povey et al., “Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex,” *Human Mutation*, vol. 34, no. 1, pp. 167–175, 2013.

[73] K. Mayer, W. Ballhausen, W. Leistner, and H.-D. Rott, “Three novel types of splicing aberrations in the tuberous sclerosis TSC2 gene caused by mutations apart from splice consensus sequences,” *Biochimica et Biophysica Acta*, vol. 1502, no. 3, pp. 495–507, 2000.

[74] L. Xu, C. Sterner, M. M. Maheshwar et al., “Alternative splicing of the tuberous sclerosis 2 (TSC2) gene in human and mouse tissues,” *Genomics*, vol. 27, no. 3, pp. 475–480, 1995.

[75] G. Panasyuk, I. Nemazanyy, A. Zhovlooup et al., “mTORβ splicing isoform promotes cell proliferation and tumorigenesis,” *Journal of Biological Chemistry*, vol. 284, no. 45, pp. 30807–30814, 2009.

[76] M.-É. Huot, G. Vogel, A. Zabarauska et al., “The Sam68 STAR RNA-binding protein regulates mTOR alternative splicing during adipogenesis,” *Molecular Cell*, vol. 46, no. 2, pp. 187–199, 2012.

[77] G. Michlewski, J. R. Sanford, and J. F. C´aceres, “The splicing factor SF2/ASF regulates translation initiation by enhancing phosphorylation of 4E-BP1,” *Molecular Cell*, vol. 30, no. 2, pp. 179–189, 2008.

[78] V. Ben-Hur, P. Denichenko, Z. Siegfried et al., “S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1,” *Cell Reports*, vol. 3, no. 1, pp. 103–115, 2013.

[79] K. W. Lynch, “Regulation of alternative splicing by signal transduction pathways,” *Advances in Experimental Medicine and Biology*, vol. 623, pp. 161–174, 2007.

[80] S. Stamm, “Regulation of alternative splicing by reversible protein phosphorylation,” *Journal of Biological Chemistry*, vol. 283, no. 3, pp. 1223–1227, 2008.

[81] J. A. McCubrey, L. S. Steelman, W. H. Chappell et al., “Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance,” *Oncotarget*, vol. 3, no. 10, pp. 1068–1111, 2012.

[82] E. S. White, R. L. Sagana, A. J. Booth et al., “Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway,” *Experimental Cell Research*, vol. 316, no. 16, pp. 2644–2653, 2010.

[83] J. C. Shultz, R. W. Goche, D. S. Wijesinghe et al., “Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of S8p30a,” *Cancer Research*, vol. 70, no. 22, pp. 9185–9196, 2010.

[84] N. A. Patel, S. Kaneko, H. S. Apostolatos et al., “Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CβII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40,” *Journal of Biological Chemistry*, vol. 280, no. 14, pp. 14302–14309, 2005.

[85] A. M. Al-Ayoubi, H. Zheng, Y. Liu, T. Bai, and S. T. Eblen, “Mitogen-activated protein kinase phosphorylation of splicing
factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion,” *Molecular and Cellular Biology*, vol. 32, no. 14, pp. 2880–2893, 2012.

[86] Z. Zhou, J. Qiu, W. Liu et al., “The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus,” *Molecular Cell*, vol. 47, no. 3, pp. 422–433, 2012.

[87] E. Allemand, S. Guil, M. Myers, J. Moscat, J. F. Cáceres, and A. R. Krainer, “Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 10, pp. 3605–3610, 2005.

[88] W. V. D. H. Van Oordt, M. T. Diaz-Meco, J. Lozano, A. R. Krainer, J. Moscat, and J. F. Cáceres, “The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation,” *Journal of Cell Biology*, vol. 149, no. 2, pp. 307–316, 2000.

[89] S. Guil, J. C. Long, and J. F. Cáceres, “hnRNP A1 relocalization to the stress granules reflects a role in the stress response,” *Molecular and Cellular Biology*, vol. 26, no. 15, pp. 5744–5758, 2006.

[90] R. Karni, Y. Hippo, S. W. Lowe, and A. R. Krainer, “The splicing-factor oncoprotein SF2/ASF activates miTORC1,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 40, pp. 15323–15327, 2008.

[91] M. Blaustein, F. Pelisch, T. Tanos et al., “Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT,” *Nature Structural & Molecular Biology*, vol. 12, no. 12, pp. 1037–1044, 2005.